Seres Therapeutics/$MCRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Ticker
$MCRB
Sector
Primary listing
Employees
103
Headquarters
Website
MCRB Metrics
BasicAdvanced
$170M
1.90
$10.22
2.89
-
Price and volume
Market cap
$170M
Beta
2.89
52-week high
$19.59
52-week low
$6.53
Average daily volume
150K
Financial strength
Current ratio
1.574
Quick ratio
1.504
Long term debt to equity
236.589
Total debt to equity
265.354
Profitability
EBITDA (TTM)
-105.499
Management effectiveness
Return on assets (TTM)
-29.57%
Return on equity (TTM)
198.97%
Valuation
Price to earnings (TTM)
1.902
Price to book
5.17
Price to tangible book (TTM)
5.17
Price to free cash flow (TTM)
-2.708
Free cash flow yield (TTM)
-36.92%
Free cash flow per share (TTM)
-7.178
Growth
Earnings per share change (TTM)
-143.68%
3-year earnings per share growth (CAGR)
-23.13%
10-year earnings per share growth (CAGR)
-19.75%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Seres Therapeutics stock?
Seres Therapeutics (MCRB) has a market cap of $170M as of August 25, 2025.
What is the P/E ratio for Seres Therapeutics stock?
The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 1.9 as of August 25, 2025.
Does Seres Therapeutics stock pay dividends?
No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of August 25, 2025.
When is the next Seres Therapeutics dividend payment date?
Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Seres Therapeutics?
Seres Therapeutics (MCRB) has a beta rating of 2.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.